TAT(SZ:002433)2022-06-15 16:00Financial Performance - The company's revenue for Q1 2022 was ¥191,252,969.09, a decrease of 75.35% compared to ¥775,917,621.13 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥37,353,612.37, an improvement of 36.89% from a loss of ¥59,185,352.61 in the previous year[4] - The net profit for the first quarter was a loss of CNY 41,251,302.09, improving from a loss of CNY 66,218,712.44 in the same period last year[26] - The basic and diluted earnings per share improved by 39.11%, increasing by ¥0.03 as the company's losses decreased compared to the previous year[11] - The basic and diluted earnings per share were both reported at -0.05, compared to -0.08 in the previous period[26] Cash Flow - The net cash flow from operating activities was ¥13,460,157.43, down 93.66% from ¥212,283,756.72 in the same period last year[4] - Cash received from sales decreased by ¥653,154,484.82, a decline of 71.87%, primarily due to a significant drop in e-commerce retail sales by subsidiary Guangdong Kangai Digital Health Technology Co., Ltd.[12] - Cash outflow from operating activities decreased by ¥448,975,282.42, a decline of 61.36%, mainly attributed to reduced procurement and VAT from the same subsidiary[13] - The net cash flow from operating activities decreased by ¥198,823,599.31, a decline of 93.66%, primarily due to the same subsidiary's reduced procurement[13] - Cash inflow from financing activities was ¥326,200,000.00, an increase from ¥295,000,000.00 in the previous year[30] - The net cash flow from financing activities was -¥33,730,652.58, compared to -¥259,408,267.27 in Q1 2021, showing an improvement[30] Assets and Liabilities - Total assets decreased by 14.99% to ¥7,546,338,017.06 from ¥8,877,327,761.62 at the end of the previous year[4] - The company's total assets decreased to CNY 7,546,338,017.06 from CNY 7,628,958,587.57[22] - The total liabilities were reported at CNY 3,004,052,136.95, down from CNY 3,044,712,285.51[22] - The equity attributable to shareholders of the parent company was CNY 4,395,453,954.47, slightly down from CNY 4,433,516,686.71[22] Expenses - The company reported a significant reduction in sales expenses by 77.81%, amounting to a decrease of ¥95,064,414.96 due to tightened liquidity[8] - Research and development expenses decreased by 55.69%, reflecting a reduction of ¥2,628,116.76 in investment from the subsidiary Guangdong Kang Aido Digital Health Technology Co., Ltd.[8] - Other income decreased by 55.62%, reflecting a reduction of ¥3,565,607.12 in government subsidies and other non-operating income[9] - The total operating costs amounted to CNY 240,371,640.52, compared to CNY 840,912,104.35 in the prior period[25] Credit and Impairment - The company experienced a 213.93% increase in credit impairment losses, amounting to a decrease of ¥15,056,726.39, due to the recovery of long-aged receivables[9] - The company reported a credit impairment loss of CNY 8,018,556.74, contrasting with a loss of CNY -7,038,169.65 in the prior period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 103,607[18] - The cash balance at the end of the reporting period was ¥51,854,052.04, down 31.53% from the beginning of the period[20] Investment Activities - Cash inflow from investment activities decreased by ¥11,776,000.00, a decline of 97.94%, due to no investment income being realized during the reporting period[14] - The company did not realize any investment income during the reporting period, leading to a 100% decrease in cash received from investment income[13] - The total cash outflow for investing activities was ¥1,074,446.81, compared to ¥9,099,361.66 in the same period last year[30] Operational Focus - The company continues to focus on cost management and operational efficiency to improve financial performance moving forward[25] - The company’s cash flow from operating activities was significantly impacted, reflecting challenges in revenue generation[29]